Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CTSA | P10619 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30556962 | 0.87 | MAPK1 (0.39) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL26122997 | 0.87 | MAPK1 (0.39) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL16778254 | 0.86 | ALDH1A1 (0.40) | ALDH1A1LMNAMAPTTDP1CYP2C9 | |
| SCHEMBL24768615 | 0.84 | LMNA (0.36) | ALDH1A1LMNAMAPTTDP1CYP2C9 | |
| SCHEMBL16419566 | 0.84 | LMNA (0.36) | ALDH1A1LMNAMAPTTDP1CYP2C9 | |
| SCHEMBL20116210 | 0.83 | CYP2C9 (0.39) | ALDH1A1LMNAMAPTTDP1CYP2C9 | |
| SCHEMBL1811481 | 0.79 | LMNA (0.57) | LMNAKMT2ACTSARAB9A | |
| SCHEMBL21381606 | 0.79 | MAPK1 (0.37) | LMNAMAPTKMT2AMEN1CTSA | |
| SCHEMBL21381662 | 0.79 | CTSA (0.34) | ALDH1A1LMNAMAPTTDP1CYP2C9 | |
| SCHEMBL21392096 | 0.78 | LMNA (0.52) | ALDH1A1LMNAMAPTKMT2ACTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225471-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2022-01-18 | — | — | US | disclosed |
| WO-2022011211-A1 | DEOXYNOJIRIMYCIN DERIVATIVES AS GLUCOSIDASE INHIBITORS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20210094938-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2021-04-01 | — | — | US | disclosed |
| EP-3709995-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2020-09-23 | — | — | EP | disclosed |
| WO-2015011252-A1 | PYRIMIDINE-PYRIDINONE SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-01-29 | — | — | WO | disclosed |
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2015011252-A1 | PYRIMIDINE-PYRIDINONE SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-01-29 | — | — | WO | disclosed |
| WO-2011137022-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-11-03 | — | — | WO | disclosed |
| WO-2007035154-A1 | NOVEL N-PYRAZINIL-PHENYLSULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035153-A1 | NOVEL PROCESS FOR THE PREPARATION OF 6-METHYL-PYRAZIN-2-YLAMINE | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225471-B2 | Antidiabetic bicyclic compounds | GPR119, GPR65, GLP1R | ALDH1A1 2734/4885LMNA 4178/4885MAPT 4367/4885 |
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | ALDH1A1 2413/4885LMNA 2523/4885MAPT 1138/4885 |
| US-20210094938-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, GPR65, GLP1R | ALDH1A1 2734/4885LMNA 4178/4885MAPT 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.